Skip to main content
European Commission logo print header

The next-generation heart pump to change patients’ lives and create a new standard of care

Descrizione del progetto

Una pompa impiantabile intelligente per l’insufficienza cardiaca avanzata

L’insufficienza cardiaca è una patologia potenzialmente letale in cui il cuore è incapace di pompare sangue a sufficienza per rispondere alle esigenze del corpo. Per i pazienti affetti da insufficienza cardiaca avanzata e per coloro che sono troppo anziani o non adatti a un trapianto di cuore, i dispositivi di assistenza ventricolare sinistra (LVAD) impiantabili sono emersi come una nuova opzione di trattamento. Il progetto Calypso, finanziato dall’UE, immetterà sul mercato un LVAD rivoluzionario sviluppato dall’azienda francese CORWAVE. Questo nuovo dispositivo si basa su una tecnologia rivoluzionaria unica e brevettata: la membrana ondulata. A differenza dei dispositivi attuali, che sono pompe rotative a flusso continuo, il LVAD di CorWave è una pompa intelligente che produce un flusso sanguigno fisiologico e pulsante, per ridare ai pazienti una vita normale con minimi effetti collaterali.

Obiettivo

Advanced heart failure (HF) is a deadly disease, with a booming incidence driven by durable socio-demographic trends. Left ventricular assist devices (LVADs) are a life-saving therapy for advanced HF patients and represent a billion-euro market. However, only 13% of the 60,000 eligible patients are implanted with current LVADs each year, due to the extremely high rate of severe adverse events (stroke, bleeding, infection) and the limited quality of life.
CorWave is an innovative French SME created in 2011 with a mission to create a new standard of care for advanced HF patients. The company is developing a game-changing LVAD, which relies on a unique and patented breakthrough technology, the wave membrane. Unlike all current devices, which are continuous-flow rotary pumps, CorWave LVAD is a smart pump producing a physiologic and pulsatile blood flow, to restore a normal life to patients with minimal side effects. CorWave LVAD will cut in half severe complications and rehospitalisation costs. CorWave projects to take over 60% of the market and reach up to €1.1 billion of turnover in 2030, by taking advantage of the LVAD market structure, which is very favourable to new entrants (concentrated on a few centres), and by increasing the penetration rate.
We have built a team of 50 experienced people, including world-class experts, and have gained a strong market traction. The clinical centres who support us through letters of intent are worth >25% of the European market. We partner with a network of industrial suppliers and have our own pilot production unit to manufacture prototypes that have proved successful in preclinical studies.
Thanks to EIC Accelerator, CorWave will transform a very promising preclinical prototype (TRL 6-7) into an industrial CE-marked medical device (TRL 8-9) that patients, clinicians and payers are waiting for. EIC Accelerator would place CorWave on a trajectory to become a global medtech leader with an outstanding socioeconomic impact on the EU.

Invito a presentare proposte

H2020-EIC-SMEInst-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-EIC-SMEInst-2018-2020-3

Meccanismo di finanziamento

SME - SME instrument

Coordinatore

CORWAVE
Contribution nette de l'UE
€ 2 495 675,00
Indirizzo
19-23 ALLEE DE L'EUROPE
92110 CLICHY
Francia

Mostra sulla mappa

PMI

L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.

Regione
Ile-de-France Ile-de-France Hauts-de-Seine
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 3 565 250,00